BridgeBio Soars After FDA OKs Rival To Pfizer's Heart Drug - Investor's Business Daily

BridgeBio will sell its drug at a slightly lower wholesale acquisition cost compared to Pfizer's blockbuster, Vyndaqel.

By: Investor's Business Daily

Nov 27 2024
0
0 Views

BridgeBio Pharma (BBIO) snagged Food and Drug Administration approval for a rival to Pfizer's (PFE) blockbuster heart drug, and BridgeBio stock catapulted by double digits. XNOW PLAYINGBiotech Stock… [+3297 chars]

Charlotte Douglas airport workers vote to strike - WSOC Charlotte

How S&P 500 tends to perform during Thanksgiving week and into New Year’s Eve - MarketWatch

Russell 2000, Dow, S&P 500 All Achieve Record Highs In Wall Street's Historic Day; Bitcoin, Gold Tumble: What's Driving Markets Monday? - Benzinga

Over 70,000 Pounds of Chicken, Pork and Beef Recalled Nationwide Due to Listeria Outbreak - EatingWell

Here's How High MicroStrategy Stock Can Climb As Bitcoin Races To New Highs - Barchart

Buffett refines plans for his fortune, donates more Berkshire shares - Reuters

Share this page

Guest Posts by Easy Branches

Banner advertising on easybranches network

all our websites